OBJECTIVES:  To assess the prevalence of skeletal-related events (SREs), the direct and indirect costs of treating bone metastases (BMs) and SREs, and the quality of life (QoL) of patients with castrate-resistant prostate cancer with BMs (bm-CRPC) in Australia, South Korea and Taiwan. METHODS:  This study utilized a hybrid approach consisting of retrospective clinical and resource use data collection via chart abstraction and cross-sectional patient-reported outcomes (PRO) data collection via the EuroQol-5 Dimensions-3 Level (EQ-5D-3L). Data was collected from 14 sites across Australia, South Korea and Taiwan. RESULTS:  Twenty-five (25) patients from Australia, 50 patients from South Korea, and 50 patients from Taiwan were enrolled. A large proportion of study patients (39.2%) had bone pain. Among patients with bone pain, 26.5% of patients were hospitalized with mean (SD) length of stay of 16.0 (21.67) days, 14.3% had surgeries, 93.9% had outpatient visits, 18.4% had emergency department (ED) visits, 24.5% had external beam radiation, 71.4% had test/scans, and 87.8% had been prescribed prostate cancer-related or pain medications. The prevalence of SREs was 3.0% [95% CI: 2.26, 3.78]. Patients with SREs represented a mean (SD) utility score of 0.3367 (0.32478) on the EQ-5D-3L. Employed patients with SREs and their caregivers reported mean (SD) of days of missed work in the past six months of 15.0 (21.2) days and 2.2 (5.9) days, respectively. Mean (SD) annual direct and indirect costs were highest for bone pain, at United States dollar (USD) 20,796.1 (USD 57,719.9) and USD 1,219.8 (USD 3,169.8), respectively.